Magnasense Past Earnings Performance

Past criteria checks 0/6

Magnasense's earnings have been declining at an average annual rate of -27.3%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 100.9% per year.

Key information

-27.3%

Earnings growth rate

1.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-100.9%
Return on equityn/a
Net Margin-118,334.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Magnasense makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:52Q Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-411038
31 Mar 240-491145
31 Dec 230-601842
30 Sep 230-3672046
30 Jun 230-3622540
31 Mar 230-3642841
31 Dec 222-3632839
30 Sep 223-884049
30 Jun 228-1004253
31 Mar 2215-943852
31 Dec 2113-923651
30 Sep 2112-1032975
30 Jun 217-812361
31 Mar 210-732252
31 Dec 200-621945

Quality Earnings: 52Q is currently unprofitable.

Growing Profit Margin: 52Q is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 52Q is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.

Accelerating Growth: Unable to compare 52Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 52Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).


Return on Equity

High ROE: 52Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies